



Workshop TDM and dose optimisation of antibiotics and antifungals

D.J. Touw

Dept. Clinical Pharmacy and Pharmacology

University of Groningen /

University Medical Center Groningen



Are you a registered hospital pharmacist (A) or a resident (B)?

A

B





Questions:

What is the most important PK parameter for the first dose of an antibiotic? Clearance or Volume of distribution?

How long is the Post Antibiotic Effect or Post MIC Effect of an aminoglycoside? 2 hours or 7 hours?

A flucloxacillin serum concentration of 40 mg/L is enough to treat an infection with a micro-organism that has a MIC value of 2 mg/L Yes or No?



What is the most important PK parameter for the first dose of an antibiotic? Clearance (A) or Volume of distribution (B)?

CL **A**

Vd **B**





How long is the Post Antibiotic Effect or Post MIC Effect of an aminoglycoside? 2 hours (A) or 7 hours (B)?

 When poll is active, respond at PollEv.com/daantouw592

 Text **DAANTOUW592** to **+31 970 0449 8375** once to join

2 H

7 H





A flucloxacillin serum concentration of 40 mg/L is enough to treat an infection with a micro-organism that has a MIC value of 2 mg/L Yes (A) or No (B)?

Yes **A**

No **B**





Case tobramycin

Male, born 8th june 1978


1,86m, 75 kg

serum creat 91 micromol/L.

Urinary infection, started with beta-lactam + tobramycine

What is your initial tobramycin dose and why?

- A) 225 mg**
- B) 375 mg**
- C) 525 mg**
- D) 750 mg**





Case tobramycin

Male, born 8th june 1978

1,86m, 75 kg

serum creat 91 micromol/L.

Urinary infection, started with beta-lactam + tobramycine

PD parameter tobramycin: $C_{max}/MIC = 10$, assume MIC of 2 mg/L

$C_{max} = Dos/V = 20$ mg/L

$Vd = 0.2-0.3$ L/kg, take 0.25 L/kg * 75 kg = 18.75 L

$Dos = 20 * 18.75 = 375$ mg (= 5 mg/kg)



Case tobramycin

Male, born 8th june 1978

1,86m, 75 kg

serum creat 91 micromol/L.

Pulmonary infection with sepsis, started with beta-lactam +
tobramycine

What is your initial tobramycin dose now?

A) 225 mg

B) 375 mg

C) 525 mg

D) 750 mg

What is your initial tobramycin dose now?

225 mg **A**

375 mg **B**

525 mg **C**

750 mg **D**





Case tobramycin

Male, born 8th june 1978

1,86m, 75 kg

serum creat 91 micromol/L.

Pulmonary infection with sepsis, started with beta-lactam +
 tobramycine

PD parameter tobramycin: $C_{max}/MIC = 10$, assume MIC of 2 mg/L

$C_{max} = Dos/V = 20$ mg/L

$Vd = 0.3-0.4$ L/kg, take 0.35 L/kg * 75 kg = 26.25 L

$Dos = 20 * 26.25 = 525$ mg (= 7 mg/kg)



Case tobramycin

Male, born 8th june 1978


1,86m, 75 kg

serum creat 91 micromol/L.

Exacerbation of his cystic fibrosis, started with beta-lactam +
tobramycine

What is your initial tobramycin dose?

- A) 225 mg**
- B) 375 mg**
- C) 525 mg**
- D) 750 mg**





Case tobramycin

Male, born 8th june 1978

1,86m, 75 kg

serum creat 91 micromol/L.

Exacerbation of his cystic fibrosis, started with beta-lactam +
 tobramycine

European Consensus Cystic Fibrosis

**$C_{max} = \text{Dos}/V = 25\text{-}30 \text{ mg/L}$ (due to limited penetration into
 sputum)**

$V_d = 0.28\text{-}0.38 \text{ L/kg}$, take $0.33 \text{ L/kg} * 75 \text{ kg} = 25 \text{ L}$

$\text{Dos} = 30 * 25 = 750 \text{ mg}$ (= 10 mg/kg)



Summary Tobramycin

Efficacy determined by C_{max}/MIC

Often poor penetration into pulmonary tissue

C_{max} mainly determined by Volume of distribution, target 20 mg/L

Vd normally: 0.2 – 0.3 L/kg

Vd in sepsis: 0.3 – 0.4 L/kg

Standard dose (based on Vd):

Non-sepsis: 5 mg/kg

Sepsis: 7 mg/kg

CF: 10 mg/kg

Note: in obese patients, take the ideal bodyweight



Case tobramycin

Male, born 8th june 1978

1,86m, 75 kg

serum creat 91 micromol/L.


Pulmonary infection, started with beta-lactam + tobramycine

Initial dose (5 mg/kg) 375 mg o.d. (Standard practice based on epidemiological susceptibility values and population Vd value: 5 mg/kg o.d. with a moderate renal function)



SIMULATIE

tobramycin [#tobramycin_adult_C1]





Case tobramycin

Male, born 8th june 1958

1,86m, 75 kg

serum creat 91 micromol/L.


Pulmonary infection, started with beta-lactam + tobramycine

Initial dose 375 mg o.d. (Standard practice 5 mg/kg o.d. with a moderate renal function)

Blood samples

1 h after start (peak level): 14 mg/L

after 10 h: 4 mg/L.





Case tobramycin

Male, born 8th june 1958

1,86m, 75 kg, serum creat 91 micromol/L.


Pulmonary infection, started with beta-lactam + tobramycin

Initial dose: 375 mg o.d. (Standard practice 5 mg/kg o.d. with a moderate renal function)

Blood samples: 1 h after start (peak level): 14 mg/L; after 10 h: 4 mg/L.

Your advice:

- A) Maintain dose and interval**
- B) Decrease dose and maintain interval**
- C) Increase dose and increase interval**
- D) Decrease dose and increase interval**



Dose advice for tobramycin

A

B

C


D





SIMULATIE


tobramycin [#tobramycin_adult_C1]





SIMULATIE

tobramycin [#tobramycin_adult_C1]





Case gentamicin

Neonate, prematurely born, birth weight 1.6 kg, open ductus botalli, treated with indomethacin i.v., signs of infection.

Indication for antibiotics (amoxicillin/gentamicin)

gentamicin started with 5 mg/kg once every 36 hours according to local protocol for neonates with infection

Target drug levels are 9-11 (peak) and ≤ 1 (trough) mg/L

Do you expect levels are met?

- A) Peak Yes, trough higher**
- B) Peak higher, trough higher**
- C) Peak lower, trough Yes**
- D) Peak lower, trough higher**

Are peak and trough met with standard dose?


A A

B B

C C

D D

Distribution of the peak level in 115 neonates treated with 5 mg/kg





Premature neonates

Volume of distribution (in L/kg) increase with decreasing gestation

Term: 0.4-0.6 L/kg

Preterm: 0.5-0.7 L/kg

Extremely premature: 0.6-0.8 L/kg



Open ductus Botalli

Blood vessel connecting the main pulmonary artery to the proximal descending aorta to bypass the fetus's fluid-filled non-functioning lungs

Closure is normally spontaneous at birth, but can be done by NSAID treatment

NSAID's reduce renal blood flow and renal drug clearance



Case gentamicin in premature neonate

Expected higher V_d and lower clearance


Expected lower peak and higher trough levels


Take samples immediately after dose and about 12 hours after dosing for dose optimisation





SIMULATIE

gentamicin [#gentamicin_neonate_ST_1500g_C1]












Case vancomycin


ICU patient (female, 63 y/o, 80 kg, 1.75 m, creatinine 180 micromol/L), catheter related infection, treated with vancomycin, 2000 mg/day continuous infusion, start 13.00.

Next day, a sample is drawn at 06.00 and the vancomycin concentration is 22 mg/L (based on $AUC > 400 \text{ mg} \cdot \text{h/L}$ target is 18-25 mg/L)

What is your opinion:

- A) Dose is fine**
- B) Dose is too low**
- C) Dose is too high**








SIMULATIE


vancomycin [#vancomycin_adult_C2]





SIMULATIE

vancomycin [#vancomycin_adult_C2]





Case flucloxacillin

ICU patient (male, 63 y/o, 80 kg, 1.80 m, creatinine 89 micromol/L, albumin 40 g/L) is treated with flucloxacillin because of an infectious endocarditis
Initial dose is 12000 mg/day as continuous infusion

Do you measure a level?

- A) No, level is OK**
- B) Yes, level may be too high**
- C) Yes, level may be too low**

Flucloxacillin in infectious endocarditis, do you measure a level?

No, Level is OK

Yes, Level may be too high

Yes, Level may be too low





Case flucloxacillin

Flucloxacillin

$$V_d = 0.25 \text{ v L/kg}$$

$$\text{Half life} = 1 \text{ h}$$

$$C_{stst} = (F \cdot D / T) * 1.44 * T_{1/2} / V_d$$

$$C_{stst} = 12000 / 24 * 1.44 * 1 / (0.25 * 80)$$

$$C_{stst} = 500 * 1.44 * 1 / 20 = 36 \text{ mg/L}$$

Seems OK



Case flucloxacillin

ICU patient (male, 63 y/o, 80 kg, 1.80 m, creatinine 89 micromol/L, albumin 40 g/L) is treated with flucloxacillin because of an infectious endocarditis, **MIC of the infecting micro-organism is 2 mg/L**

Initial dose is 12000 mg/day as continuous infusion

Do you measure a level?

- A) No, level is OK
- B) Yes, level may be too high
- C) Yes, level may be too low

Flucloxacillin in infective endocarditis, do you measure a level?

No, Level is OK

Yes, Level may be too high

Yes, Level may be too low





Case flucloxacillin

Flucloxacillin

$V_d = 0.25 \text{ L/kg}$, half life = 1 h

$C_{stst} = (F \cdot D / T) * 1,44 * T_{1/2} / V_d = 36 \text{ mg/L}$

Protein binding is 95%

Free concentration is $0.05 * 36 = 1.8 \text{ mg/L}$

So yes, because level may be too low.



Case flucloxacillin

ICU patient (male, 63 y/o, 80 kg, 1.80 m, creatinine 89 micromol/L, **albumin 20 g/L**) is treated with flucloxacillin because of an infectious endocarditis, MIC of the infecting micro-organism is 2 mg/L **and the patient shows twitches**

Initial dose is 12000 mg/day as continuous infusion

Do you measure a level?

- A) No, level is OK
- B) Yes, level may be too high
- C) Yes, level may be too low

Flucloxacillin in infective endocarditis, do you measure a level?

No, level is OK

Yes, level may be too high

Yes, level may be too low





Case flucloxacillin

Flucloxacillin

Vd = 0.25 L/kg, half life = 1 h

Cstst = (F*D/T) * 1,44 * T_{1/2}/Vd = 36 mg/L

Patient suffers from hypoalbuminemia

Free concentration is increased

Patient may develop neurological side effects

So yes, because level may be too high



Case voriconazole

Patient (70 kg) with an invasive fungal infection and inflammation starts with a loading dose of twice daily 400 mg i.v. followed by a maintenance dose of twice daily 300 mg i.v.

Do you measure blood levels?

- A. No, is SmPC dose**
- B. No, no PK/PD relationship**
- C. Yes, levels may be too high**
- D. Yes, levels may be too low**

Patient with i.v. voriconazole, do you want drug levels?

- A No, is SmPC dose and not necessary
- B No, no PK/PD relationship
- C Yes, levels may be too high
- D Yes, levels may be too low





Case voriconazole: PK/PD relationship

Retrospective (n=201)

IFI: possible, probable,
proven

Outcome: partial,
complete, failure

Incident	No. of patients with incident/ total no. with indicated concn (%)		<i>P</i> value ^a
Treatment failure	<1.7 mg/liter	≥1.7 mg/liter	
All treatment patients (<i>n</i> = 163) ^b	19/74 (26)	6/89 (7)	<0.01
Proven or probable IFI (<i>n</i> = 67)	12/34 (35)	2/33 (6)	<0.01
Visual/auditory hallucinations	≤5 mg/liter	>5 mg/liter	
All patients (<i>n</i> = 201)	2/170 (1.2)	10/31 (32)	<0.01



TABLE 3 Factors associated with a significant change in voriconazole concentration identified from multiple linear regression analysis^a

Model term	Coefficient	95% Confidence interval		P value
		Lower	Upper	
Oral administration ^b	-1.348	-1.741	-0.955	<0.01
Age (yr) ^c	0.026	0.017	0.036	<0.01
Weight (kg)	-0.028	-0.038	-0.018	<0.01
Daily dose (mg)	0.005	0.003	0.006	<0.01
Concomitant medication				
CYP2C19 inducer ^d	-2.367	-3.181	-1.553	<0.01
Prednisone/prednisolone	-1.012	-1.346	-0.678	<0.01
Methylprednisolone	-1.833	-2.445	-1.221	<0.01
Dexamethasone	-1.245	-1.991	-0.500	<0.01
Omeprazole	1.141	0.575	1.706	<0.01
Pantoprazole	0.685	0.330	1.041	<0.01
Esomeprazole	1.009	0.192	1.826	<0.05
Rabeprazole	1.414	0.800	2.028	<0.01



CYP450 enzymes:

2C19*17 => ultra rapid

2C19*1 => extensive metabolizer


2C19*2/*3 => poor metabolizer

6-fold difference

VORICONAZOLE

	UR ¹	EM	HEM	PM
T _{max} , h		1.3 (0.5-3.0)	1.0 (0.5-1.5)	1.5 (0.5-3.1)
C _{trough} , µg/L		968 ± 772	2636 ± 1471	4139 ± 1010
C _{max} , µg/L		3212 ± 1307	5780 ± 2094	7210 ± 1510
AUC _τ , µg·h/L	10 000	19 305 ± 9594	42 369 ± 19 090	58 697 ± 11 113
T _{1/2} , h		9.6 ± 5.1	16.9 ± 7.2	32.3 ± 9.4
CL _{ss} /F, L/h		12.6 ± 6.5	5.9 ± 3.5	3.5 ± 0.9


¹Wang Eur J Clin Pharmacol 2009, Lee J Clin Pharmacol 2011



“SLOW”

“FAST”


Case voriconazole: PK/CRP relationship





Case voriconazole: PK/CRP relationship

Interleukin-2
modulates
CYP2C19
activity





Voriconazole

Saturable metabolism

Modulated by:

- drug-drug interactions (through CYP 2C19 and 3A4)
- Pharmacogenetics
- State of inflammation

Close monitoring is warranted



Summary

Aminoglycosides are dosed on peak and trough levels, do not wait for steady state, first dose kinetics

Beta-lactam are preferably given as continuous infusion and dosed on free drug concentration

Azoles are dosed on trough levels, voriconazole is very sensitive for interactions and endogenous effects on pharmacokinetics



THANK YOU



d.j.touw@umcg.nl